Kevin Hughes is 57 and was diagnosed with prostate cancer a year ago, at which point his PSA levels were in the 500s. After an MRI and biopsies he was treated with the hormone therapy injections Zoladex, and experienced all of the most common side effects of hormone therapy including hot sweats and fatigue. “You name it, I had all the textbook side effects,” Kevin says.
Kevin was told he may be eligible to be part of the STAMPEDE trial, which looks at hormone therapy in combination with other treatments. Kevin was recruited to the arm of the trial which saw him receiving abiraterone and prednisolone plus standard care.
Abiraterone should definitely be an option for men who haven’t had chemotherapy.
While hormone therapy injections had helped drive Kevin’s PSA down sharply, abiraterone continued to hammer it down with no side effects. His PSA was checked only a couple of weeks ago and has dropped to 0.02. “It’s all been the good side with none of the down sides,” Kevin tells us. “Abiraterone should definitely be an option for men who haven’t had chemotherapy. Every man is different but just look at my results – it turbo charged the effects of treatment and it was really heartening to see my PSA levels dropping. As far as my experience has been concerned it’s ticked all the boxes.”
The STAMPEDE trial is looking at men who have recently been diagnosed with prostate cancer that has spread outside the prostate, or is at risk of spreading outside the prostate. It is looking to see whether having other treatments at the same time as hormone therapy controls the cancer better. At the moment, abiraterone is only licensed for men whose cancer is no longer responding to hormone therapy. So men on the STAMPEDE trial may get abiraterone at an earlier stage than you would on the NHS.
Read more about abiraterone.